NCT05423522: Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
- State
- Completed
- Phase
- Phase 2
- People
- 72 taking part
- Started
- 20 May 2022
- Primary completion
- 23 Jan 2024
- Arms
- NanoLithium® NP03
- Results
- None posted
- 20 May 2022: Trial started
- 21 Jun 2022: Trial registered
- 29 Oct 2024: Trial completed